Does adding immunotherapy to neoadjuvant chemotherapy increase postoperative morbidity in gastroesophageal junction adenocarcinoma? A propensity score-matched study - Takeaways - MDSpire

Does adding immunotherapy to neoadjuvant chemotherapy increase postoperative morbidity in gastroesophageal junction adenocarcinoma? A propensity score-matched study

  • By

  • Huiliang Zhang

  • Qingwen Huang

  • Jitao Du

  • Xiangbin Wan

  • July 3, 2026

  • 0 min

Share

  • 1

    This study evaluated postoperative morbidity in patients with gastroesophageal junction adenocarcinoma receiving neoadjuvant immunotherapy plus chemotherapy.

  • 2

    A total of 400 patients were included, with 140 receiving neoadjuvant immunotherapy and 260 receiving neoadjuvant chemotherapy alone.

  • 3

    The primary outcome showed no significant difference in major complications between the NICT and NCT cohorts.

  • 4

    NICT was associated with improved major pathological regression rates compared to NCT, but not with increased postoperative morbidity.

  • 5

    The findings suggest that adding immunotherapy to neoadjuvant chemotherapy does not significantly increase surgical risk for GEJ adenocarcinoma.

Original Source(s)

Does adding immunotherapy to neoadjuvant chemotherapy increase postoperative morbidity in gastroesophageal junction adenocarcinoma? A propensity score-matched study

  • by Huiliang Zhang, Qingwen Huang, Jitao Du, Xiangbin Wan

  • July 3, 2026

Related Content

Editorial: National Colorectal Cancer Awareness Month 2025: Current Progress and Future Prospects on Colorectal Cancer Prevention, Diagnosis and Treatment

2026 ASCO Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates

  • July 2, 2026

  • 1 min
Immunotherapy does not impair ovarian function in a mouse model of breast cancer